

=====
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported) October 31, 2006

HAEMONETICS CORPORATION

(Exact name of registrant as specified in its charter)

Massachusetts 1-10730 04-2882273
(State or other jurisdiction (Commission (I.R.S. Employer
of incorporation) File Number) Identification No.)

400 Wood Road 02184
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code 781-848-7100

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

- [ ] Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))

ITEM 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION

On October 31, 2006 Haemonetics Corporation (the "Company") issued a press
release announcing financial results for the second quarter and six months ended
September 30, 2006. A copy of the release is furnished with this report as
exhibit 99.1.

The information in this current report on Form 8-K and the exhibit attached
hereto shall not be deemed "filed" for the purposes of Section 18 of the
Securities and Exchange Act of 1934 (the "Exchange Act") or otherwise subject to
the liabilities of that section, nor shall it be deemed incorporated by
reference in any filing under the Securities Act of 1933 or the Exchange Act,
regardless of any general incorporation language in such filing.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS

(d) Exhibits

99.1: Press Release of Haemonetics Corporation dated October 31, 2006 announcing
financial results for the second quarter and six months ended
September 30, 2006.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

HAEMONETICS CORPORATION  
-----  
(Registrant)

Date: October 31, 2006

/s/ RONALD J. RYAN  
-----  
Ronald J. Ryan,  
Vice President and  
Chief Financial Officer

HAEMONETICS(R) REPORTS SECOND QUARTER FISCAL 2007 FINANCIAL RESULTS AND  
AFFIRMS ANNUAL REVENUE PRO FORMA AND EPS GUIDANCE

BRAINTREE, Mass., Oct. 31 /PRNewswire-FirstCall/ -- Haemonetics Corporation (NYSE: HAE) reported second quarter fiscal 2007 GAAP net revenue of \$108 million, up 8.0% over prior year, and year-to-date GAAP net revenue of \$219 million, up 7.6% over the first half of 2006.

Brad Nutter, Haemonetics' President and CEO, said, "The growth drivers of our business, namely plasma, red cells, and the OrthoPAT(R) system, continued to perform well in the quarter. In fact, total disposables sales, which make up nearly 90% of total revenues, grew 11% in the quarter. We're pleased with this growth, particularly when we consider that equipment sales declined 33.5%, \$2 million, as we compared to a very strong quarter last year."

Diluted GAAP net earnings per share were \$0.05 for the quarter, down 88.5% from 2Q:06 and \$0.44 year-to-date, down 48.4%. As previously announced, Haemonetics' financial results were impacted by three items: FAS 123R required stock option expense, restructuring costs in connection with changes to the Company's international operations, and an in-process R&D charge arising from the second quarter acquisition of Arryx. Thus, GAAP financials results were impacted as follows: FAS 123R (pre-tax) charges of \$2 million, or \$0.06 per share, for the quarter, and \$5 million, or \$0.13 per share, year-to-date; restructuring (pre-tax) charges of \$1 million, or \$0.03 per share, for the quarter, and \$3 million, or \$0.06 per share, year-to-date; and, an in-process R&D (pre and after tax) charge of \$9 million, or \$0.33 per share, for the quarter and year-to-date.

Excluding the charges noted above, Haemonetics' pro forma diluted net earnings per share were \$0.46 for the quarter, up 15.0%, and \$0.97 year-to-date, up 11.0%.

#### FINANCIAL RESULTS

Other pro forma results versus FY06 are as follows:

- \* Revenue of \$108 million for Q2:07, up 8.0%, and \$219 million year-to-date, up 7.6%
- \* Gross profit of \$55 million for Q2:07, up 6.7%, and \$113 million year-to-date, up 6.0%
- \* Operating expense of \$38 million for Q2:07, up 3.2%, and \$75 million year-to-date, up 4.0%
- \* Operating income of \$18 million for Q2:07, up 14.9%, and \$37 million year-to-date, up 10.1%
- \* Earnings per share \$0.46 for Q2:07, up 15.0%, and \$0.97 year-to-date, up 11.0%
- \* Gross margin of 50.9% for Q2:07, down 60 basis points, and 51.4% year-to-date, down 80 basis points
- \* Operating margin of 16.3% for Q2:07, up 100 basis points, and 17.0% year-to-date, up 40 basis points
- \* Tax rate of 34.6% in Q2:07 versus 33.3% in Q2:06, and 34.8% year-to-date, level with prior year

Haemonetics also reported the following GAAP results versus FY06:

- \* Revenue of \$108 million for Q2:07, up 8.0%, and \$219 million year-to-date, up 7.6%
- \* Gross profit of \$55 million for Q2:07, up 6.6%, and \$113 million year-to-date, up 5.9%
- \* Operating expense of \$50 million for Q2:07, up 36.7%, and \$92 million year-to-date, up 27.1%
- \* Operating income of \$5 million for Q2:07, down 66.1%, and \$20 million year-to-date, down 40.2%
- \* Earnings per share of \$0.05 for Q2:07, down 88.5%, and \$0.44 year-to-date, down 48.4%
- \* Gross margin of 50.8% for Q2:07, down 70 basis points, and 51.3% year-to-date, down 90 basis points

\* Operating margin of 4.8% for Q2:07, down 1030 basis points, and 9.1% year-to-date, down 740 basis points

#### BALANCE SHEET

Haemonetics' cash and short term investments declined \$8.5 million, for a cash balance of \$242 million. In Q2 Haemonetics initiated a share repurchase program and spent \$14 million to repurchase 305,000 shares of its common stock. The Company has \$26 million remaining under the \$40 million Board authorization. The Company generated \$16 million in cash flow from operating activities for the quarter and \$33.5 million year-to-date.

#### DONOR PRODUCT LINE

For the quarter, plasma disposable sales benefited from continued growth in U.S. and European plasma collections and from several new customer contracts. Worldwide plasma disposables revenue was \$32 million for the quarter, up 23.6% over Q2:06, and \$64 million year-to-date, up 20.0%.

Stephen Swenson, General Manager of the Global Plasma Business, said, "We're ahead of our schedule to place 800 plasma devices in the year, having placed 600 devices year-to-date. Recent statistics show that demand for intravenous immunoglobulin, a key driver of plasma collections, is growing at greater than 10% per year."

Worldwide blood bank disposables revenue was \$32 million for the quarter, down 1.6% from Q2:06, and \$63 million year-to-date, down 2.8%. Platelet disposables comprise the majority of blood bank sales. The platelet market is mature with collections remaining level as collection efficiencies offset an increased demand for platelets.

Red cell disposables revenue continues to benefit from a favorable shift in product mix as well as from unit growth in the U.S. U.S. revenue grew 20%. Worldwide red cell disposables revenue was \$10 million for the quarter, up 16.5% over Q2:06, and \$21 million year-to-date, up 20.8%. As announced earlier in the quarter, Haemonetics signed a multi-year agreement with the American Red Cross to continue the use of Haemonetics' red cell collection technology at twenty-one Red Cross regions across the U.S.

#### PATIENT PRODUCT LINE

The Company reported strong progress in its transition to direct U.S. sales of the OrthoPAT system. U.S. OrthoPAT disposables revenue grew 86.8%. Worldwide OrthoPAT disposables revenue was \$7 million, up 56.2% over Q2:06, and \$15 million year-to-date, up 44.6%. OrthoPAT revenue growth was driven by price improvement and new customers.

Surgical disposables revenue, principally sales of the Cell Saver(R) systems, was \$15 million in the quarter, down 1.9% from Q2:06, and \$32 million year-to-date, down 0.6%. As previously stated, Haemonetics is maintaining its market share, but demand for Cell Saver 5+ continues to decline as surgical advances allow for lower blood loss surgeries. The Cell Saver system is principally used in high blood loss surgeries. New product sales are expected to positively impact Surgical disposable sales in the second half of the year.

In the quarter, Haemonetics announced the U.S. market launch of the SmartSuction(R) Solo(TM) auto-regulating surgical suction device. The SmartSuction Solo system is Haemonetics' first product to expand its reach beyond blood salvage into blood management. The system addresses a \$230 million market.

#### OTHER PRODUCTS

Equipment sales in the quarter were \$4 million, down 33.5% from 2Q:06, and \$10 million year-to-date, down 21.4%. Equipment sales are not recurring and can be opportunistic. Equipment sales comparisons were against Q2:06 when sales were up 157% due to the introduction of the Cell Saver 5+ system and sales of ACP(R) 215 systems.

Services and Software sales grew to \$8 million in the quarter, up 12.5% over 2Q:06, and \$14 million year-to-date, up 11.4%. Services/software sales growth has been strong over the past 18 months, and its revenue is now of the size where growth is having a meaningful impact on the Company's total revenue. Sales growth has been driven largely by software sales in our 5D(TM) Information Management division.

#### FY07 GUIDANCE

The Company affirmed its pro forma FY07 guidance measures, with the exception of gross margin. As noted previously, the product growth mix shift to plasma products will affect Haemonetics' gross margins for the year. As such, Haemonetics updated its gross margin guidance from approximately 52% to approximately 51%. FY07 pro forma guidance will be measured against pro forma FY06 results. Annual FY07 pro forma guidance is:

- \* Revenue growth of 10-14%
- \* Gross margin of approximately 51%
- \* Operating income growing approximately 17%
- \* Operating margins improving to approximately 18%
- \* Earnings per share in the range of \$2.05-\$2.17

Haemonetics has posted potential income and revenue scenarios reflecting the high and low ranges of guidance on its website at <http://www.haemonetics.com>.

For comparison purposes, the FY06 pro forma results exclude the benefit of an arbitration award received in the third quarter which added \$26.4 million to operating income and \$0.62 to earnings per share.

The FY07 guidance is based on anticipated annual pro forma results that exclude three items: 1) the impact from stock compensation expense (FAS 123R), expected to be approximately \$10 million (pre-tax), or \$0.25 per share with costs spread throughout the year; 2) a restructuring charge of \$3-4 million (pre-tax), or \$0.07 to \$0.09 per share, with costs spread throughout the year; and 3) an in-process R&D charge of \$9 million (pre and after tax), or \$0.33 per share, related to the Company's acquisition of Arrayx, taken in the second quarter.

As the Company's in-process R&D charge is lower than expected, Haemonetics is raising its FY07 GAAP earnings per share to a range of \$1.38 to \$1.52 (from a range of \$1.15 to \$1.29).

In FY07, the Company expects to generate \$35-\$40 million of operating cash flow, Haemonetics' internal cash flow measurement.

#### CONFERENCE CALL

Haemonetics will hold a conference call on Tuesday, October 31st at 10:00 am Eastern. The call will discuss the second quarter results. Interested parties can participate in the conference call by dialing (888) 868-9083 (U.S. only) or (973) 935-8512 with conference ID 7929614. The call will be replayed through November 14th at (877) 519-4471 (U.S. only) or (973) 341-3080 using PIN 7929614.

Haemonetics (NYSE: HAE) is a global company engaged in the design, manufacture and worldwide marketing of automated blood processing systems. These systems address important medical markets: surgical blood salvage, blood component collection, plasma collection, and blood component safety. To learn more about Haemonetics' products and markets, visit its web site at <http://www.haemonetics.com>.

Haemonetics has presented supplemental non-GAAP financial results as part of this release which exclude stock compensation expense, restructuring costs and an in-process research and development charge and other unusual items associated with the acquisition of Arrayx. Haemonetics believes that these non-GAAP results are useful to investors because it allows for an evaluation of the Company with a focus on the results of our core business.

This release contains forward-looking statements that involve risks and uncertainties, including technological advances in the medical field and standards for transfusion medicine and our ability to successfully implement products that incorporate such advances and standards, product demand, market acceptance, regulatory uncertainties, the effect of economic and political conditions, the impact of competitive products and pricing, blood product reimbursement policies and practices, foreign currency exchange rates, changes in customers' ordering patterns, the effect of industry consolidation as seen in the plasma market, the effect of communicable diseases and the effect of uncertainties in markets outside the U.S. (including Europe and Asia) in which we operate and other risks detailed in the Company's filings with the Securities and Exchange Commission. The foregoing list should not be construed as exhaustive. The forward-looking statements are based on estimates and assumptions made by management of the Company and are believed to be reasonable, though are inherently uncertain and difficult to predict. Actual results and experience could differ materially from the forward-looking statements.

CONTACT:

Julie Fallon

Tel. (781) 356-9517

Alternate Tel. (617) 320-2401

fallon@haemonetics.com

HAEMONETICS CORPORATION FINANCIAL SUMMARY  
(UNAUDITED DATA IN THOUSANDS, EXCEPT PER SHARE DATA)  
CONSOLIDATED STATEMENTS OF INCOME  
FOR THE SECOND QUARTER FYE07

	9/30/06 As Reported -----	10/01/05 As Reported (1) -----	% Inc/(Dec) vs Prior Year -----
NET REVENUES	\$ 108,487	\$ 100,488	8.0%
Gross profit	55,162	51,765	6.6
R&D	6,119	6,283	(2.6)
S,G&A	34,741	30,103	15.4
In-Process R&D	9,073	0	---
Cost to Equity	73	187	(61.0)
Operating expenses	50,006	36,573	36.7
Operating income	5,156	15,192	(66.1)
Interest expense	(421)	(522)	(19.3)
Interest income	1,951	1,083	80.1
Other income/(expense), net	425	481	(11.6)
Income before taxes	7,111	16,234	(56.2)
Tax expense	5,845	5,476	6.7
NET INCOME	\$ 1,266	\$ 10,758	(88.2)
Net income per common share assuming dilution	\$ 0.05	\$ 0.39	(88.5)%
Weighted average number of shares			
Basic	27,087	26,395	
Diluted	27,969	27,354	

	9/30/06 As Reported	10/01/05 As Reported (1)	Inc/(Dec) vs prior year profit margin %
	-----	-----	-----
Profit Margins:			
Gross profit	50.8%	51.5%	(0.7)%
R&D	5.6%	6.3%	(0.7)%
S,G&A	32.0%	30.0%	2.0%
Operating income	4.8%	15.1%	(10.3)%
Income before taxes	6.6%	16.2%	(9.6)%
Net income	1.2%	10.7%	(9.5)%

CONSOLIDATED STATEMENTS OF INCOME FOR FYE07 YEAR TO DATE

	9/30/06 As Reported	10/01/05 As Reported (1)	% Inc/(Dec) vs Prior Year
	-----	-----	-----
NET REVENUES	\$ 219,161	\$ 203,661	7.6%
Gross profit	112,535	106,289	5.9
R&D	11,541	11,824	(2.4)
S,G&A	71,649	60,591	18.3
In-Process R&D	9,073	0	---
Cost to Equity	225	362	(37.8)
Operating expenses	92,488	72,777	27.1
Operating income	20,047	33,512	(40.2)
Interest expense	(846)	(1,063)	(20.4)
Interest income	3,977	2,396	66.0
Other income/(expense), net	1,337	1,345	(0.6)
Income before taxes	24,515	36,190	(32.3)
Tax expense	12,093	12,723	(5.0)
NET INCOME	\$ 12,422	\$ 23,467	(47.1)
Net income per common share assuming dilution	\$ 0.44	\$ 0.86	(48.4)%
Weighted average number of shares			
Basic	26,993	26,338	
Diluted	27,948	27,279	

	9/30/06 As Reported	10/01/05 As Reported (1)	Inc/(Dec) vs prior year profit margin %
	-----	-----	-----
Profit Margins:			
Gross profit	51.3%	52.2%	(0.9)%
R&D	5.3%	5.8%	(0.5)%
S,G&A	32.7%	29.8%	2.9%
Operating income	9.1%	16.5%	(7.4)%
Income before taxes	11.2%	17.8%	(6.6)%
Net income	5.7%	11.5%	(5.8)%

REVENUE ANALYSIS FOR THE SECOND QUARTER FYE07

	9/30/06 As Reported -----	10/01/05 As Reported -----	% Inc/(Dec) -----
Revenues by Geography			
United States	\$ 46,811	\$ 37,930	23.4%
International	61,676	62,558	(1.4)
Net Revenues	\$ 108,487	\$ 100,488	8.0%
Disposable Revenues by Product Family			
Donor:			
Plasma	\$ 32,072	\$ 25,938	23.6%
Blood Bank	31,678	32,193	(1.6)
Red Cell	10,373	8,903	16.5
	\$ 74,123	\$ 67,034	10.6
Patient:			
Surgical	15,108	15,394	(1.9)
OrthoPAT	7,085	4,536	56.2
	\$ 22,193	\$ 19,930	11.4
Subtotal	\$ 96,316	\$ 86,964	10.8
Equipment	\$ 4,405	\$ 6,623	(33.5)
Misc & Service	7,766	6,901	12.5
Net Revenues	\$ 108,487	\$ 100,488	8.0%

REVENUE ANALYSIS FOR FYE07 YEAR TO DATE

	9/30/06 As Reported -----	10/01/05 As Reported -----	% Inc/(Dec) -----
Revenues by Geography			
United States	\$ 93,231	\$ 76,153	22.4%
International	125,930	127,508	(1.2)
Net Revenues	\$ 219,161	\$ 203,661	7.6%
Disposable Revenues by Product Family			
Donor:			
Plasma	\$ 63,891	\$ 53,241	20.0%
Blood Bank	63,044	64,883	(2.8)
Red Cell	20,973	17,358	20.8
	\$ 147,908	\$ 135,482	9.2
Patient:			
Surgical	32,309	32,490	(0.6)
OrthoPAT	14,641	10,125	44.6
	\$ 46,950	\$ 42,615	10.2
Subtotal	\$ 194,858	\$ 178,097	9.4
Equipment	\$ 10,013	\$ 12,734	(21.4)
Misc & Service	14,290	12,830	11.4
Net Revenues	\$ 219,161	\$ 203,661	7.6%



CONSOLIDATED BALANCE SHEETS

	Period ending	
	09/30/06	4/1/06(1)
Assets		
Cash & cash equivalents	\$ 242,200	\$ 250,667
Short-term investments	--	--
Accounts receivable, net	84,001	86,901
Inventories, net	58,925	54,571
Other current assets	28,679	26,265
Total current assets	413,805	418,404
Net PP&E	80,757	75,266
Other assets	66,870	51,787
Total assets	\$ 561,432	\$ 545,457

	Period ending	
	09/30/06	4/1/06(1)
Liabilities & Stockholders' Equity		
S/T debt & current maturities	\$ 21,922	\$ 26,176
Other current liabilities	66,193	61,940
Total current liabilities	88,115	88,116
Long-term debt	12,690	12,977
Other long-term liabilities	3,637	3,800
Stockholders' equity	456,990	440,564
Total liabilities & equity	\$ 561,432	\$ 545,457

SECOND QUARTER FYE07  
CONSOLIDATED STATEMENTS OF INCOME ADJUSTED FOR THE EFFECT OF STOCK  
BASED COMPENSATION EXPENSE, RESTRUCTURING COSTS & ARRYX IPRD AND  
OTHER UNUSUAL CHARGES

	9/30/06 As Reported	Arryx IPRD and Other Unusual(2)	09/30/06 Effect of Stock-Based Compensation Expense(3)	Restructuring Costs(4)	9/30/06 As Adjusted(5)
	-----	-----	-----	-----	-----
Net Revenue	\$ 108,487	\$ 0	\$ 0	\$ 0	\$ 108,487
Gross profit	55,162	0	(48)	0	55,210
R&D	6,119	0	74	0	6,045
S,G&A	34,741	0	2,145	1,106	31,490
In-Process					
R&D	9,073	9,073	0	0	0
Cost to					
Equity	73	73	0	0	0
Operating expenses	50,006	9,146	2,219	1,106	37,535
Operating income	5,156	(9,146)	(2,267)	(1,106)	17,675
Interest expense	(421)	0	0	0	(421)
Interest income	1,951	0	0	0	1,951
Other income/ (expense), net	425	0	0	0	425
Income before taxes	7,111	(9,146)	(2,267)	(1,106)	19,630
Tax expense	5,845	0	(575)	(381)	6,801
NET INCOME	\$ 1,266	\$ (9,146)	\$ (1,692)	\$ (725)	\$ 12,829
Net income per common share assuming dilution	\$ 0.05	\$ (0.33)	\$ (0.06)	\$ (0.03)	\$ 0.46
Weighted average number of shares					
Basic	27,087	27,087	27,087	27,087	27,087
Diluted	27,969	27,969	27,969	27,969	27,969

SECOND QUARTER FYE07  
CONSOLIDATED STATEMENTS OF INCOME ADJUSTED FOR THE EFFECT OF STOCK  
BASED COMPENSATION EXPENSE, RESTRUCTURING COSTS & ARRYX IPRD AND  
OTHER UNUSUAL CHARGES

	9/30/06 As Adjusted(5)	10/1/05 As Adjusted(6)	Adjusted % Inc/(Dec) vs Prior Year
	-----	-----	-----
NET REVENUES	\$ 108,487	\$ 100,488	8.0%
Gross profit	55,210	51,765	6.7
R&D	6,045	6,283	(3.8)
S,G&A	31,490	30,103	4.6
In-Process R&D	0	0	---
Cost to Equity	0	0	---
Operating expenses	37,535	36,386	3.2
Operating income	17,675	15,379	14.9
Interest expense	(421)	(522)	(19.3)
Interest income	1,951	1,083	80.1
Other income/ (expense), net	425	481	(11.6)
Income before taxes	19,630	16,421	19.5
Tax expense	6,801	5,476	24.2
NET INCOME	\$ 12,829	\$ 10,945	17.2
Net income per common share assuming dilution	\$ 0.46	\$ 0.40	15.0%
Weighted average number of shares			
Basic	27,087	26,395	
Diluted	27,969	27,354	

	9/30/06 As Reported	9/30/06 As Adjusted(5)	10/01/05 As Adjusted(6)	Inc/(Dec) vs prior year profit margin %
	-----	-----	-----	-----
Profit Margins:				
Gross profit	50.8%	50.9%	51.5%	(0.6)%
R&D	5.6%	5.6%	6.3%	(0.7)%
S,G&A	32.0%	29.0%	30.0%	(1.0)%
Operating income	4.8%	16.3%	15.3%	1.0%
Income before taxes	6.6%	18.1%	16.3%	1.8%
Net income	1.2%	11.8%	10.9%	0.9%

FYE07 YEAR TO DATE  
CONSOLIDATED STATEMENTS OF INCOME ADJUSTED FOR THE EFFECT OF STOCK BASED  
COMPENSATION EXPENSE, RESTRUCTURING COSTS & ARRYX IPRD AND OTHER UNUSUAL  
CHARGES

	9/30/06 Reported	Arryx IPRD and Other Unusual(2)	09/30/06 Effect of Stock-Based Compensation Expense(3)	Restructuring Costs(4)	9/30/06 As Adjusted(5)
	-----	-----	-----	-----	-----
NET REVENUES	\$ 219,161	\$ 0	\$ 0	\$ 0	\$ 219,161
Gross profit	112,535	0	(112)	0	112,647
R&D	11,541	0	174	0	11,367
S,G&A	71,649	0	5,008	2,667	63,974
In-Process R&D	9,073	9,073	0	0	0
Cost to Equity	225	225	0	0	0
Operating expenses	92,488	9,298	5,182	2,667	75,341
Operating income	20,047	(9,298)	(5,294)	(2,667)	37,306
Interest expense	(846)	0	0	0	(846)
Interest income	3,977	0	0	0	3,977
Other income/ (expense), net	1,337	0	0	0	1,337
Income before taxes	24,515	(9,298)	(5,294)	(2,667)	41,774
Tax expense	12,093	0	(1,531)	(927)	14,551
NET INCOME	\$ 12,422	\$ (9,298)	\$ (3,763)	\$ (1,740)	\$ 27,223
Net income per common share assuming dilution	\$ 0.44	\$ (0.33)	\$ (0.13)	\$ (0.06)	\$ 0.97
Weighted average number of shares					
Basic	26,993	26,993	26,993	26,993	26,993
Diluted	27,948	27,948	27,948	27,948	27,948

FYE07 YEAR TO DATE  
CONSOLIDATED STATEMENTS OF INCOME ADJUSTED FOR THE EFFECT OF STOCK BASED  
COMPENSATION EXPENSE, RESTRUCTURING COSTS & ARRYX IPRD AND OTHER UNUSUAL  
CHARGES

	9/30/06 As Adjusted(5)	10/1/05 As Adjusted(6)	Adjusted % Inc/(Dec) vs. Prior Year
	-----	-----	-----
NET REVENUES	\$ 219,161	\$ 203,661	7.6%
Gross profit	112,647	106,289	6.0
R&D	11,367	11,824	(3.9)
S,G&A	63,974	60,591	5.6
In-Process R&D	0	0	---
Cost to Equity	0	0	---
Operating expenses	75,341	72,415	4.0
Operating income	37,306	33,874	10.1
Interest expense	(846)	(1,063)	(20.4)
Interest income	3,977	2,396	66.0
Other income/ (expense), net	1,337	1,345	(0.6)
Income before taxes	41,774	36,552	14.3
Tax expense	14,551	12,723	14.4
NET INCOME	\$ 27,223	\$ 23,829	14.2
Net income per common share assuming dilution	\$ 0.97	\$ 0.87	11.5%
Weighted average number of shares			
Basic	26,993	26,338	
Diluted	27,948	27,279	

	9/30/06 As Reported	9/30/06 As Adjusted(5)	10/01/05 As Adjusted(6)	Inc/(Dec) vs prior year profit margin %
	-----	-----	-----	-----
Profit Margins:				
Gross profit	51.3%	51.4%	52.2%	(0.8)%
R&D	5.3%	5.2%	5.8%	(0.6)%
S,G&A	32.7%	29.2%	29.8%	(0.6)%
Operating income	9.1	17.0%	16.6%	0.4%
Income before taxes	11.2	19.1%	17.9%	1.2%
Net income	5.7%	12.4%	11.7%	0.7%

- (1) Reflects the adjustment to convert our investment in Arrayx, Inc. to the equity method for periods prior to the acquisition.
- (2) IPRD and Cost to Equity impact of Arrayx acquisition
- (3) Stock based compensation expense related to the adoption of FAS 123R.
- (4) Restructuring costs primarily include severance and related costs associated with eliminating or reorganizing certain positions in our international business operations.
- (5) "As Adjusted" for FY07 is comprised of "As Reported" less the "Effect of Stock Based Compensation", "Restructuring Costs" & "Arrayx IPRD and Other Unusual Charges."
- (6) "As Adjusted" for FY 06 excludes the restatement of our financial results to reflect our investment in Arrayx on the equity method.

SOURCE Haemonetics Corporation

-0-

10/31/2006

/CONTACT: Julie Fallon of Haemonetics Corporation, +1-781-356-9517 or

+1-617-320-2401, fallon@haemonetics.com /

/Web site: <http://www.haemonetics.com> /